In November 2015 the Medical Technologies Evaluation Programme commenced the review of this guidance, to register as a stakeholder please contact us at email@example.com.
NICE has developed medical technology guidance on the Vision Amniotic Leak Detector (ALD).
NICE medical technologies guidance addresses specific technologies notified to NICE by manufacturers. The ‘case for adoption’ recommendations are based on the claimed advantages of introducing the specific technology compared with current management of the condition. This ‘case’ is reviewed against the evidence submitted and expert advice. If the case for adopting the technology is supported, then the technology has been found to offer advantages to patients and the NHS. The specific recommendations on individual technologies are not intended to limit use of other relevant technologies which may offer similar advantages.
NICE has said that the Vision ALD should be considered for pregnant women with unexplained vaginal wetness. Healthcare teams may want to use the Vision ALD because it can exclude leaking amniotic fluid as a cause of vaginal wetness and would avoid women needing a physical examination, which can be uncomfortable. Offering the Vision ALD in the community (by a midwife or other healthcare worker in a GP practice, or by a midwife in the woman’s home) would result in cost savings by preventing unnecessary referrals to antenatal units.